SHARE TO:

MEXPHARM

  •  

    find pharmacy

    Komposisi:

    Meloxicam

    Bentuk sediaan:

    - Tiap tablet mengandung Meloxicam 7,5 mg dan 15 mg.

    - Tiap 1,5 mL injeksi mengandung Meloxicam 15 mg.

    - Tiap supositoria mengandung Meloxicam 15 mg.

    Farmakologi:

    Meloxicam merupakan obat anti-inflamasi non steroid golongan asam enolat. Ikatan protein plasma 99%. Dimetabolisme menjadi bentuk tidak aktif dan diekskresikan lewat urine dan feses dengan waktu paruh sekitar 20 jam. Total klirens plasma 7-8 mL.menit. Kadar mantap dicapai dalam waktu 3-5 hari.

    Indikasi:

    Terapi simptomatik jangka pendek untuk osteoarthritis eksaserbasi akut, terapi simptomatik jangka panjang untuk arthritis reumatoid.

    shopping online

    Dosis:

    - Arthritis reumatoid: 15 mg perhari. Tergantung respons terapeutik, dosis dapat dikurangi hingga 7,5 mg perhari.

    - Osteoarthritis: 7,5 mg perhari. Bila perlu dosis dapat ditingkatkan hingga 15 mg perhari.

    - Pada pasien yang mempunyai risiko peningkatan efek samping: dosis awal mulai 7,5 mg perhari.

    Kontraindikasi:

    Hipersensitif terhadap Meloxicam, gejala-gejala asma, polip hidung, angio-edema atau urtikaria, ulkus lambung yang aktif, insufisiensi hepar dan ginjal yang berat. Anak-anak dan remaja kurang dari 15 tahun, masa kehamilan dan menyusui, perdarahan gastrointestinal, otak atau sejenisnya.

    Peringatan dan Perhatian:

    - Penggunaan hingga 3 tahun dapat meningkatkan risiko efek kardiovaskuler: kejadian trombolitik kardiovaskuler.

    - Dapat menyebabkan munculnya hipertensi baru atau memperberat hipertensi yang sudah ada.

    - Dapat terjadi retensi cairan, inflamasi dan perdarahan saluran cerna.

    Efek Samping:

    Dispepsia, mual, muntah, anemia, pruritus dsb

     

     

    find pharmacy

    MEXPHARM

     

    Composition:

    Meloxicam

    Presentation:

    - Each tablet contains Meloxicam 7,5 mg and 15 mg. - Each 1,5 mL injection contains Meloxicam 15 mg. - Each suppositoria contains Meloxicam 15 mg

    Pharmacology:

    Meloxicam is an enolic acid non-steroidal anti-inflammatory drug. Plasma protein bonds 99%. Metabolized into an inactive form and excreted through urine and feces with a half-life of about 20 hours. Total plasma clearance 7-8 mL / minute. Steady levels are achieved within 3-5 days.

    Indications:

    Short-term symptomatic therapy for acute exacerbation of osteoarthritis, long-term symptomatic therapy for rheumatoid arthritis.

    Contraindications:

    Hypersensitivity to Meloxicam, symptoms of asthma, nasal polyps, angio-edema or urticaria, active gastric ulcer, severe hepatic and renal insufficiency. Children and adolescents less than 15 years, during pregnancy and lactation, gastrointestinal bleeding, brain or the like.

    shopping online

    Dosage:

    - Rheumatoid arthritis: 15 mg per day. Depending on the therapeutic response, the dose can be reduced to 7.5 mg per day. - Osteoarthritis: 7.5 mg per day. If necessary, the dose can be increased to 15 mg per day. - In patients who have an increased risk of side effects: the initial dose starts at 7.5 mg daily.

    Warning and Precautions:

    - Use of up to 3 years can increase the risk of cardiovascular effects: cardiovascular thrombolytic events. - Can cause the emergence of new hypertension or aggravate existing hypertension. - Fluid retention, inflammation and gastrointestinal bleeding can occur.

    Adverse events:

    In common with all adhesive products, some cases of irritation and / or skin surrounding the wound have been reported. It should be noted that use of frequent dressing changes, especially with patients with fragile skin, can result in skin stripping. Infrequent cases of sensitivity to the dressing have been reported. If reddening or sensation occurs, discontinue use.

    Drugs Interaction:

    This medication may increase the risk of bleeding when taken with other drugs that also may cause bleeding. Examples include anti-platelet drugs such as clopidogrel, anticoagulant such as dabigatran/enoxaparin/warfarin.

Please login or register to post comments.